The BASA Study: Breath Analysis for Severe Asthma Patients

The BASA Study: Breath Analysis for Severe Asthma Patients. A New, Non-invasive Approach for the Monitoring of Inflammation in Severe Asthma Patients on Biologics

This study will evaluate the fluctuations of exhaled breath markers in patients with severe asthma on biologics. In the study, severe asthma patients will be followed up to 16 weeks monitoring lung function and inflammation through non-invasive technologies such as exhaled breath analysis (FeNO, GC-MS and EBC). A control group will be followed up to two weeks with the overall objective to indentify and evaluate the modifcations of markers of inflammation in patient under biologic treatment.

Inclusion Criteria:

• Severe asthma diagnosis according to the latest recommendation
• Eligible or in treatment with a biologic treatment for severe asthma
• Able to follow istructions
• Able and willing to sign the informed consent

Exclusion Criteria:

• Not able to perform lung function measurements and the procedures of the study
• Acute respiratory or non respiratory infection (<4 weeks)
• Not willing to continue the study